BACKGROUND: The predictors of cardiovascular events in patients with chronic refractory angina are limited. High-sensitivity cardiac troponin T (hs-cTnT) assays are biomarkers that may be used to determine the prognosis of patients with stable coronary artery disease. HYPOTHESIS: Hs-cTnT is a predictor of death and nonfatal myocardial infarction (MI) in patients with refractory angina. METHODS: We prospectively enrolled 117 consecutive patients in this study. A heart team ruled out myocardial revascularization feasibility after assessing recent coronary angiograms; evidence of myocardial ischemia served as an inclusion criterion. Optimal medical therapy was encouraged via outpatient visits every 6 months; plasma hs-cTnT levels were determined at baseline. The primary endpoint was the composite incidence of death and nonfatal MI. RESULTS: During a median follow-up period of 28.0 months (interquartile range, 18.0-47.5 months), an estimated 28.0-month cumulative event rate of 13.4% was determined via the Kaplan-Meier method. Univariate predictors of the composite endpoint were hs-cTnT levels and LV dysfunction. Following a multivariate analysis, only hs-cTnT was independently associated with the events in question, either as a continuous variable (hazard ratio per unit increase in the natural logarithm: 2.83, 95% confidence interval: 1.62-4.92, P < 0.001) or as a categorical variable (hazard ratio for concentrations above the 99th percentile: 5.14, 95% confidence interval: 2.05-12.91, P < 0.001). CONCLUSIONS: In patients with chronic refractory angina, plasma concentration of hs-cTnT is the strongest predictor of death and nonfatal MI. Notably, none of the outcomes in question occurred in patients with baseline plasma levels <5.0 ng/L.
BACKGROUND: The predictors of cardiovascular events in patients with chronic refractory angina are limited. High-sensitivity cardiac troponin T (hs-cTnT) assays are biomarkers that may be used to determine the prognosis of patients with stable coronary artery disease. HYPOTHESIS: Hs-cTnT is a predictor of death and nonfatal myocardial infarction (MI) in patients with refractory angina. METHODS: We prospectively enrolled 117 consecutive patients in this study. A heart team ruled out myocardial revascularization feasibility after assessing recent coronary angiograms; evidence of myocardial ischemia served as an inclusion criterion. Optimal medical therapy was encouraged via outpatient visits every 6 months; plasma hs-cTnT levels were determined at baseline. The primary endpoint was the composite incidence of death and nonfatal MI. RESULTS: During a median follow-up period of 28.0 months (interquartile range, 18.0-47.5 months), an estimated 28.0-month cumulative event rate of 13.4% was determined via the Kaplan-Meier method. Univariate predictors of the composite endpoint were hs-cTnT levels and LV dysfunction. Following a multivariate analysis, only hs-cTnT was independently associated with the events in question, either as a continuous variable (hazard ratio per unit increase in the natural logarithm: 2.83, 95% confidence interval: 1.62-4.92, P < 0.001) or as a categorical variable (hazard ratio for concentrations above the 99th percentile: 5.14, 95% confidence interval: 2.05-12.91, P < 0.001). CONCLUSIONS: In patients with chronic refractory angina, plasma concentration of hs-cTnT is the strongest predictor of death and nonfatal MI. Notably, none of the outcomes in question occurred in patients with baseline plasma levels <5.0 ng/L.
Authors: Eduard M Laufer; Alma M A Mingels; Mark H M Winkens; Ivo A P G Joosen; Mark W M Schellings; Tim Leiner; Joachim E Wildberger; Jagat Narula; Marja P Van Dieijen-Visser; Leonard Hofstra Journal: Arterioscler Thromb Vasc Biol Date: 2010-03-18 Impact factor: 8.311
Authors: Stephan D Fihn; Julius M Gardin; Jonathan Abrams; Kathleen Berra; James C Blankenship; Apostolos P Dallas; Pamela S Douglas; Joanne M Foody; Thomas C Gerber; Alan L Hinderliter; Spencer B King; Paul D Kligfield; Harlan M Krumholz; Raymond Y K Kwong; Michael J Lim; Jane A Linderbaum; Michael J Mack; Mark A Munger; Richard L Prager; Joseph F Sabik; Leslee J Shaw; Joanna D Sikkema; Craig R Smith; Sidney C Smith; John A Spertus; Sankey V Williams Journal: J Am Coll Cardiol Date: 2012-11-19 Impact factor: 24.094
Authors: C Mannheimer; P Camici; M R Chester; A Collins; M DeJongste; T Eliasson; F Follath; I Hellemans; J Herlitz; T Lüscher; M Pasic; D Thelle Journal: Eur Heart J Date: 2002-03 Impact factor: 29.983
Authors: Stefan Verheye; E Marc Jolicœur; Miles W Behan; Thomas Pettersson; Paul Sainsbury; Jonathan Hill; Mathias Vrolix; Pierfrancesco Agostoni; Thomas Engstrom; Marino Labinaz; Ranil de Silva; Marc Schwartz; Nathalie Meyten; Neal G Uren; Serge Doucet; Jean-François Tanguay; Steven Lindsay; Timothy D Henry; Christopher J White; Elazer R Edelman; Shmuel Banai Journal: N Engl J Med Date: 2015-02-05 Impact factor: 91.245
Authors: Torbjørn Omland; James A de Lemos; Marc S Sabatine; Costas A Christophi; Madeline Murguia Rice; Kathleen A Jablonski; Solve Tjora; Michael J Domanski; Bernard J Gersh; Jean L Rouleau; Marc A Pfeffer; Eugene Braunwald Journal: N Engl J Med Date: 2009-11-25 Impact factor: 91.245
Authors: Timothy D Henry; Daniel Satran; James S Hodges; Randall K Johnson; Anil K Poulose; Alex R Campbell; Ross F Garberich; Bradley A Bart; Rachel E Olson; Charlene R Boisjolie; Karen L Harvey; Theresa L Arndt; Jay H Traverse Journal: Eur Heart J Date: 2013-05-12 Impact factor: 29.983
Authors: Martin Andrassy; H Christian Volz; Bjoern Maack; Alena Schuessler; Gitsios Gitsioudis; Nina Hofmann; Danai Laohachewin; Alexandra R Wienbrandt; Ziya Kaya; Angelika Bierhaus; Evangelos Giannitsis; Hugo A Katus; Grigorios Korosoglou Journal: PLoS One Date: 2012-12-17 Impact factor: 3.240
Authors: Nilson T Poppi; Luís H W Gowdak; Luciana O C Dourado; Eduardo L Adam; Thiago N P Leite; Bruno M Mioto; José E Krieger; Luiz A M César; Alexandre C Pereira Journal: Clin Cardiol Date: 2016-10-18 Impact factor: 2.882